Tenaya Therapeutics Files Definitive Proxy Materials
Ticker: TNYA · Form: DEFA14A · Filed: Apr 16, 2026
Sentiment: neutral
Topics: proxy, governance, SEC filing
Related Tickers: TNYA
TL;DR
Tenaya Therapeutics (TNYA) filed proxy docs on 4/16/26 - shareholders vote soon.
AI Summary
Tenaya Therapeutics, Inc. filed a DEFA14A on April 16, 2026, which includes additional definitive proxy soliciting materials. The filing details information related to the company's corporate governance and shareholder matters, with its principal executive offices located at 171 Oyster Point Blvd., Suite 500, South San Francisco, CA 94080.
Why It Matters
This filing provides shareholders with crucial information for upcoming votes, impacting the company's direction and governance.
Risk Assessment
Risk Level: low — This is a routine proxy filing and does not contain new financial or strategic information that would inherently increase risk.
Key Players & Entities
- Tenaya Therapeutics, Inc. (company) — Filer of the DEFA14A
- 0001858848 (company) — CIK number for Tenaya Therapeutics, Inc.
- 2026-04-16 (date) — Filing date of the DEFA14A
- 171 Oyster Point Blvd., Suite 500 South San Francisco CA 94080 (location) — Mailing and Business Address for Tenaya Therapeutics, Inc.
FAQ
What type of SEC filing is this?
This is a DEFA14A filing, which represents Additional definitive proxy soliciting materials and Rule 14(a)(12) material.
When was this filing submitted to the SEC?
The filing date was April 16, 2026.
What is the CIK number for Tenaya Therapeutics, Inc.?
The CIK number for Tenaya Therapeutics, Inc. is 0001858848.
Where are Tenaya Therapeutics, Inc.'s principal offices located?
The company's mailing and business address is 171 Oyster Point Blvd., Suite 500, South San Francisco, CA 94080.
What is the SIC code associated with Tenaya Therapeutics, Inc.?
The SIC code is 2836, which pertains to Biological Products, (No Diagnostic Substances).
Filing Details
This Form DEFA14A (Form DEFA14A) was filed with the SEC on April 16, 2026 regarding Tenaya Therapeutics, Inc. (TNYA).